Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice

Endocrinology

Volumn 151, Issue 6, 2010, Pages 2641-2648

  Weinstein, Robert S ^a   Jilka, Robert L ^a   Almeida, Maria ^a   Roberson, Paula K ^a   Manolagas, Stavros C ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; PREDNISOLONE; PROTEIN KINASE B; WNT PROTEIN; PARATHYROID HORMONE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE DENSITY; BONE DISEASE; BONE STRENGTH; CELL SURVIVAL; CELL VIABILITY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFICACY; ENZYME PHOSPHORYLATION; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OSTEOID; PRIORITY JOURNAL; SELF EVALUATION; SIGNAL TRANSDUCTION; TRABECULAR BONE; ANIMAL; BONE; BONE DEVELOPMENT; CELL LINE; CYTOLOGY; DRUG EFFECT; METABOLISM; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE AND BONES; BONE DENSITY; CELL LINE; GLUCOCORTICOIDS; MICE; OSTEOBLASTS; OSTEOCYTES; OSTEOGENESIS; PARATHYROID HORMONE; PREDNISOLONE;

EID: 77954505723     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-1488     Document Type: Article

References (49)

1. Reeve J, Williams D, Hesp R, Hulme P, Klenerman L, Zanelli JM, Darby AJ, Tregear GW, Parsons JA 1976 Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1:1035-1038
2. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK 2005 Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688-703
3. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse corticosteroidinduced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627-1633
4. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R 2007 Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028-2039
5. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR 2009 Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirtysix-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346-3355
6. Jilka RL 2007 Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40:1434-1446
7. Gasser JA, Kneissel M, Thomsen JS, Mosekilde L 2000 PTH and interactions with bisphosphonates. J Musculoskelet Neuronal Interact 1:53-56
8. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH 1995 The anabolic effect of human PTH (1-34)on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate - is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603-610
9. Cosman F, Lindsay R 1998 Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence. Calcif Tissue Int 62:475-480
10. Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, Yao W, Jee WS, Sato M 2003 New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 144:2008-2015
11. Samadfam R, Xia Q, Goltzman D 2007 Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res 22:55-63
12. Weinstein RS 2001 Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2:65-73
13. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC 1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of the deleterious effects on bone. J Clin Invest 102:274-282
14. Dempster DW 1989 Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 4:137-141
15. Dempster DW, Arlot MA, Meunier PJ 1983 Mean wall thickness and formation periods of trabecular bone packets in corticosteroidinduced osteoporosis. Calcif Tissue Int 35:410-417
16. Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC 2002 Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 109:1041-1048
17. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC 1999 Increased bone formation by prevention of osteoblast apoptosis with PTH. J Clin Invest 104:439-446
18. Kleiber M 1961 The fire of life: an introduction to animal energetics. Chaps 10, 11. New York: John Wiley, Sons, Inc.
19. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 2:595-610
20. O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS 2004 Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835-1841
21. Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, Kousteni S, O'Brien CA, Bellido T, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC 2007 Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 282:27285-27297
22. Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC 2007 Perspective - quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res 22:1492-1501
23. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW 1998 Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512
24. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN 1995 The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81:727-736
25. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL 1999 Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. J Cell Biochem 74:357-371
26. Fu Q, Jilka RL, Manolagas SC, O'Brien CA 2002 Parathyroid hormone stimulates receptor activator of NFκB ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP response element-binding protein. J Biol Chem 277:48868-48875
27. Partridge NC, Alcorn D, Michelangeli VP, Ryan G, Martin TJ 1983 Morphological and biochemical characterization of four clonal osteogenic sarcoma cell lines of rat origin. Cancer Res 43:4308-4314
28. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T 1999 Prevention of osteocyte and osteoblasts apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363-1374
29. StatCorp 2005 Stata statistical software, release 8.2. College Station, TX: Stata Corp.
30. Weinstein RS, Jia D, Powers CC, Stewart SA, Jilka RL, Parfitt AM, Manolagas SC 2004 The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology 145:1980-1987
31. Smith E, Frenkel B 2005 Glucocorticoids inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in a glycogen synthase kinase-3β-dependent and -independent manner. J Biol Chem 280:2388-2394
32. Stevenson JC 1998 Management of corticosteroid-induced osteoporosis. Lancet 352:1327-1328
33. Rubin MR, Bilezikian JP 2002 The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 87:4033-4041
34. Manolagas SC, Weinstein RS, Jilka RL, Parfitt AM 1998 Parathyroid hormone and corticosteroid-induced osteoporosis. Lancet 352:1940
35. Oxlund H, Ortoft G, Thomsen JS, Danielsen CC, Ejersted C, Andreassen TT 2006 The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone 39:244-252
36. Liu X, Bruxvoort KJ, Zylstra CR, Liu J, Cichowski R, Faugere MC, Bouxsein ML, Wan C, Williams BO, Clemens TL 2007 Lifelong accumulation of bone in mice lacking Pten in osteoblasts. Proc Natl Acad Sci USA 104:2259-2264
37. Yamamoto T, Kambe F, Cao X, Lu X, Ishiguro N, Seo H 2007 Parathyroid hormone activates phosphoinositide 3-kinase-Akt-Bad cascade in osteoblast-like cells. Bone 40:354-359
38. Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, Ritchie RO, Lane NE 2008 Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 58:3485-3497
39. Hayashi K, Yamaguchi T, Yano S, Kanazawa I, Yamauchi M, Yamamoto M, Sugimoto T 2009 BMP/Wnt antagonists are upregulated by dexamethasone in osteoblast and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 379:261-266
40. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL 2005 Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577-4583
41. O'Brien CA, Plotkin LI, Vyas K, Cazer PE, Gortazar AR, Goellner JJ, Chen J, Shleton R, Weinstein RS, Schipani E, Jilka RL, Manolagas SC, Bellido T 2006 Activation of PTH receptor 1 specifically in osteocytes suppresses Sost expression and increases bone mass in transgenic mice. J Bone Miner Res 20:S4
42. Wan M, Yang C, Li J, Wu X, Yuan H, Ma H, He X, Nie S, Chang C, Cao X 2008 Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev 22:2968-2979
43. Kramer I, Keller H, Leupin O, Kneissel M 2010 Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metab 21:237-244
44. Kramer I, Loots GG, Studer A, Keller H, Kneissel M 2010 Parathyroid hormone (PTH) induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25:178-189
45. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S 2005 Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by β-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem 280:41342-41351
46. Wang FS, Ko JY, Weng LH, YehD W, Ke HJ, Wu SL 2009 Inhibition of glycogen synthase kinase-3β attenuates glucocorticoid-induced bone loss. Life Sci 85:685-692
47. Weinstein RS 2010 Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity. Bone 46:564-570
48. Weinstein RS, Wan C, Liu Q, Wang Y, Almeida M, O'Brien CA, Roberson PK, Boskey AL, Clemens TL, Manolagas SC 2010 Endogenous glucocorticoids decrease vascularity and increase skeletal fragility in aged mice. Aging Cell 9:147-161
49. Jilka R, Climer L, DeLoose A, Nagarajan R, O'Brien CA, Weinstein R, Manolagas S 2009 Balanced remodeling in response to sustained PTH elevation requires osteoclastic bone resorption, sclerostin suppression, as well as increased angiogenesis. J Bone Miner Res 24(Suppl 1) A09001656 (Abstract)